Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Jinyun Dong, Zuodong Qin, Weidong Zhang, et al.
Drug Resistance Updates (2020) Vol. 49, pp. 100681-100681
Closed Access | Times Cited: 201

Showing 1-25 of 201 citing articles:

Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies
Alessia Catalano, Domenico Iacopetta, Jessica Ceramella, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 616-616
Open Access | Times Cited: 282
Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance
Yuan Li, Zhiyuan Xu, Shanming Ruan, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 260
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Luciana Mosca, Andrea Ilari, Francesco Fazi, et al.
Drug Resistance Updates (2021) Vol. 54, pp. 100742-100742
Closed Access | Times Cited: 218
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)
Hang Zhang, Hai‐Wei Xu, Charles R. Ashby, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 1, pp. 525-555
Closed Access | Times Cited: 201
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Simin Qi, Jinyun Dong, Zhiyuan Xu, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 201
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance
Jing‐Quan Wang, Yuqi Yang, Chao‐Yun Cai, et al.
Drug Resistance Updates (2021) Vol. 54, pp. 100743-100743
Closed Access | Times Cited: 172
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez‐Ruiz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 166
Therapeutic strategies to overcome taxane resistance in cancer
Tuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100754-100754
Closed Access | Times Cited: 143
Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
Jinyun Dong, Xiangdong Cheng, Weidong Zhang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8884-8915
Closed Access | Times Cited: 138
Novel nanomedicines to overcome cancer multidrug resistance
Zhenwei Su, Shaowei Dong, Shan‐Chao Zhao, et al.
Drug Resistance Updates (2021) Vol. 58, pp. 100777-100777
Closed Access | Times Cited: 134
Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
Sepideh Mirzaei, Mohammad Gholami, Farid Hashemi, et al.
Drug Discovery Today (2021) Vol. 27, Iss. 2, pp. 436-455
Open Access | Times Cited: 127
Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges
Chunyan Duan, Mingjia Yu, Jiyuan Xu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114643-114643
Open Access | Times Cited: 120
Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability
Thi‐Thao‐Linh Nguyen, Van‐An Duong, Han‐Joo Maeng
Pharmaceutics (2021) Vol. 13, Iss. 7, pp. 1103-1103
Open Access | Times Cited: 115
Lemon‐Derived Extracellular Vesicles Nanodrugs Enable to Efficiently Overcome Cancer Multidrug Resistance by Endocytosis‐Triggered Energy Dissipation and Energy Production Reduction
Qian Xiao, Wei Zhao, Chentian Wu, et al.
Advanced Science (2022) Vol. 9, Iss. 20
Open Access | Times Cited: 94
Intracellular Mutual Amplification of Oxidative Stress and Inhibition Multidrug Resistance for Enhanced Sonodynamic/Chemodynamic/Chemo Therapy
Shaoqi Guan, Xijian Liu, Chunlin Li, et al.
Small (2022) Vol. 18, Iss. 13
Closed Access | Times Cited: 79
Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer
Jianyou Gu, Wenjie Huang, Xianxing Wang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 71
Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review
Jinyun Dong, Yuan Li, Can Hu, et al.
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108488-108488
Closed Access | Times Cited: 58
P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators
Yang Guo, Milad Ashrafizadeh, Murtaza M. Tambuwala, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 11, pp. 104161-104161
Closed Access | Times Cited: 18
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 2
Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs
Wenxiao Jiang, Jun Xia, Shangdan Xie, et al.
Drug Resistance Updates (2020) Vol. 50, pp. 100683-100683
Closed Access | Times Cited: 114
Synthesis, characterization, X-ray, HOMO-LUMO, MEP, FT-IR, NLO, Hirshfeld surface, ADMET, boiled-egg model properties and molecular docking studies with human cyclophilin D (CypD) of a Schiff base compound: (E)-1-(5-nitro-2-(piperidin-1-yl)phenyl)-N-(3-nitrophenyl)methanimine
Songül Şahin, Necmi Dege
Polyhedron (2021) Vol. 205, pp. 115320-115320
Closed Access | Times Cited: 98
Current scenario of indole derivatives with potential anti-drug-resistant cancer activity
Yanshu Jia, Xiaoyue Wen, Yufeng Gong, et al.
European Journal of Medicinal Chemistry (2020) Vol. 200, pp. 112359-112359
Closed Access | Times Cited: 97
Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
Simin Qi, Gang Cheng, Xiangdong Cheng, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 89
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
Mingyang Tang, Xiao Hu, Yi Wang, et al.
Pharmacological Research (2020) Vol. 163, pp. 105207-105207
Open Access | Times Cited: 84
Inhibition of NPC1L1 disrupts adaptive responses of drug‐tolerant persister cells to chemotherapy
Zhe Zhang, Siyuan Qin, Yan Chen, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 2
Open Access | Times Cited: 65
Page 1 - Next Page

Scroll to top